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A B S T R A C T
Purpose: To determine the etiology of short-term mortality in patients with status epilepticus (SE).
Methods: 920 episodes of SE were recorded among 750 patients in a 10-year period. According to the
clinical assessment, sequence of events that led to death in a particular case showed two major causes of
death: (1) underlying disease, and (2) complications caused by convulsions, therapy or coma.
Results: Among 920 episodes of SE, 120 (13%) patients passed away. 79 patients (65.8%) died due to the
underlying disease and 27 patients (22.5%) died of the combination caused by complications of
underlying disease, convulsions, therapy, and/or coma. Among remaining 14 patients (11.7%), underlying
disease was not the cause of death. Those 14 patients suffered complications caused by convulsions,
therapy, and comawhich caused death in four; therapy and coma in three; therapy in three; coma in two;
and convulsions and coma in two patients, in the order already mentioned.
Conclusions: Among approximately 9 out of 10 patients with SE, death was the result of underlying
disease. Although with very few patients, additional factors could provoke fatal complications of SE. In
case of 1 among 10 patients complications caused by coma, therapy, and/or convulsions were the
immediate cause of death. In case of such patients timely and adequate treatment could prevent death.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Studies from the 19th and early 20th century indicate that SE
resulted in a dramatic course and grave prognosis with a
considerable rate of mortality (according to 1,2). In the last few
decades, the rate of mortality has been decreasing most likely due
to the improved treatment.3 It is estimated that the SE mortality is
3.6–4.0/100,000 per year.4 However, these ﬁgures do not explain
relative contribution of various factors to mortality as well as its
wide variability.
Death is a common outcome of SE caused by a severe
symptomatic underlying disease. Nevertheless, death following
an episode of SE caused by cryptogenic, idiopathic, or chronic non-
progressive disease is exceptional.5,6 In patients with SE that
started during the hospital stay for reason other than epilepsy, the
mortality rate was especially high (61%), with approximately one-
third dying during SE, and two-thirds after its termination.7
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2.1. Period of study
This study encircles a period of 10 years from January the 1st
1988 until December the 31st 1997 at the Institute of Neurology
Clinical Center of Serbia, Belgrade.
2.2. Population of patients
Patients of both genders, older than 12 years with SE were
included.
2.3. Management of patients
Paramedics and emergency physicians initially treatedmajority
of patients during transfer to hospital. Approximately 20% of
patients were transferred from another hospital in uninterrupted
SE. Upon admission, they were initially treated by residents in
emergency room (ER) and transferred to the neurology intensive
care unit (ICU), which is equipped with facilities for vital function
monitoring, and ventilator support supervised by neurologist. Only
patients with respiratory depression (RD) were artiﬁciallyvier Ltd. All rights reserved.
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ICU and they were not included in our study.
2.4. Surveillance of SE
For each SE episode vital parameters and total number of
generalized tonic–clonic (GTC) seizures were observed, as well as
the duration of SE, and time from the application of effective
antiepileptic drug (AED) to the SE severance.
2.5. Therapeutic protocol
Patients were treated according to the standardized hospital-
wide therapeutic protocol. However, during the 10-year period the
protocol was occasionally violated mainly due to a periodic lack of
particular AED on local market.
2.6. Deﬁnition of SE
SE is deﬁned as ‘‘a condition in which epileptic activity persists
for 30 min or longer, causing a wide spectrum of clinical
symptoms’’,2 and short-term mortality as death during the ﬁrst
30 days following episode of SE.10 SE cessation was clinically
deﬁned as a complete abolition of convulsions with normalization
of autonomic parameters for GTC and partial motor (PM) SE, and
abolishing of abnormal stereotype behavior with regaining of
consciousness for non-convulsive SE. For all patients with non-
convulsive SE and majority of patients remaining in coma for at
least 4 h, EEG conﬁrmed SE severance as soon as possible during
regular working hours.
2.7. Classiﬁcation of SE
In collaboration with the attending physician one of us (D.V.S.)
classiﬁed SE according to clinical and, if available, EEG criteria.
2.8. Criteria for etiology of death
The etiology of death was determined for each patient. In each
case of death, two types of etiologies and their combinations were
determined: (1) severe underlying disease, and (2) complications
caused by convulsions, therapy, and/or coma with no signs of
severe underlying disease. Criteria for differentiation between
etiologies depended on clinical assessment of the sequence of
events that led to death in each particular case. If several etiologies
contributed to death, their combination was considered as the
principal cause. If complication of the severe underlying disease
contributed to death, it was regarded as the most important,
because neither SE nor other complications would have appeared
in absence of the underlying disease.
2.9. Diagnosis of underlying disease
Diagnosis of underlying disease was made by the integration of
clinical data and the results of complementary examination.
Available anamnestic data were collected, and detailed physical,
neurological examinations and CT scans were performed on all
patients. Brain MRI was performed on approximately 1 among 3
patients according to availability at the time of study. ECG, EEG,
blood biochemistry, complete blood count and chest X-ray, CSF
examination, VDRL, various serological, toxicological, and bacter-
iological and virusological (mainly antibody titers for Herpes
simplex I and II viruses, and HIV) tests were used frequently. Other
tests were performed when that was justiﬁed. In majority of
deceased patients, clinical presentation of underlying diseases wasobvious and fulﬁlled the criteria for the diagnosis of particular type
of disease. According to prevalent prognosis, different etiologies
were classiﬁed as severe (that could lead to death) or benign (that
usually do not lead to death).
2.10. Deﬁnition of complications caused by convulsions
Complications of vigorous convulsions resulted from powerful
and protracted muscle contractions and comprised tongue bite,
rhabdomyolysis, physical injuries, and RD.
2.11. Deﬁnition of complications caused by therapy
Antistatus therapy complications were related to intravenous
application of the AED. RD, apnea, and cardiac arrest were
complications caused by therapy only in cases when they occurred
immediately (approximately within 10 min) following intrave-
nous application of the antistatus drug. Criteria for RD were
decrease of ventilator effort, cyanosis and direct demonstration of
the increase of pCO2 and decrease of pO2 in arterial blood. Apnea
was diagnosed as severance of breathing with no tendency for
spontaneous recovery during at least 30 s.
2.12. Deﬁnition of complications caused by coma
Coma was the consequence of the underlying disease,
prolonged convulsions, or late complication of antistatus therapy.
Regarding the fact that coma causes complications not because of
its etiology, but only because of its duration, it was recognized as
the independent morbogenic factor. Complications that were
caused by coma were consequence of prolonged immobility and
included bedsores, infections, venous thromboses and embolism,
or corneal perforation. The longer the duration of coma the more
serious were the complications. Although coma complications
were among the most serious, majority were preventable or
curable.
2.13. Statistical tests
The following statistical tests were used in: Chi square test;
Mann–Whitney’s test; signed rank sum test; Friedman’s test;
Kruskal–Wallis’ test; non-parametric Spearman’s correlation,
Student’s t test; analysis of variance; and normal and binomial
distribution test.
3. Results
3.1. Whole population
During a 10-year period, therewere 920 SE episodes among 750
patients. Two patients hadmore than 10 SE episodes, 9 had 5–9, 24
had 3–4, 42 had 2 and 673 (73.1%) patients had a single SE episode.
In case of 873 (94.9%) episodes, SE started before the admission to
hospital and in 47 (5.1%) cases after the admission. Six hundred
and two (65.4%) episodes were intercurrent and 318 (34.6%) were
initial. SE was classiﬁed as GTC (725, 78.8%), PM (98, 10.7%), non-
convulsive (93, 10%) or myoclonic (4 patients, 0.5%). EEG was
performed in 102 (11%) episodes during and in 761 (82.7%) after
the termination of SE. Among patients who died (120 of them) EEG
was performed with 73 patients (60.1%).
3.2. Treatment of SE
Majority of patients (60.6%) were treated with more than
one AED. Initial AEDs were intravenous diazepam (591) and
Table 1
Causes of death in patients with SE.
Underlying diseases contribute No. Underlying diseases do not contribute No.
(1) Underlying disease, no other complications 79 (8) Complications caused by convulsions, therapy and comaa 4
(2) Underlying disease, complications caused by therapy 9 (9) Complications caused therapya 3
(3) Underlying disease, complications caused by coma 8 (10) Complications caused by therapy, and comaa 3
(4) Underlying disease, complications caused by therapy and coma 4 (11) Complications caused by comaa 2
(5) Underlying disease, complications caused by convulsions, therapy and coma 3 (12) Complications caused by convulsions and comaa 2
(6) Underlying disease, complications caused by convulsions and therapy 2
(7) Underlying disease, complications caused by convulsions and coma 1
Total 106 14
Grand total 120
a Death was not the consequence of complications caused by the underlying disease.
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and phenytoin (166 patients). AEDs which inﬂuenced SE ﬁnally to
stop were diazepam (351), midazolam (228), phenobarbital (149),
phenytoin (86), thiopental (23), and other (27 patients). SE
terminated spontaneously in case of 12 patients, and after
intramuscular application of less than 10 mg of diazepam or less
than 15 mg of midazolam in case of 30 patients. Twelve patients
died because SE could not be aborted by antiepileptic drug therapy.
3.3. Patients who died
During the period of 10 years, 120 (13%) patients with SE died.
In majority of cases diagnosis was established on the basis of
clinical presentation and antemortem examinations. Average age
of deceased patients with SE was signiﬁcantly higher compared to
those who survived (53  15.5 and 40.3  15.4 years, respectively;
p = 0.0001). Among those who died, GTC SE (83.3% vs. 78.1%), PM SE
(13.4% vs. 10.2%) and myoclonic SE (0.8% vs. 0.4%), were more
frequent while non-convulsive SE (2.5% vs. 11.3%) was less frequent
compared with patients who survived (p = 0.015). Duration of SE was
signiﬁcantly longer (p = 0.0001) with patients who died (median:
4.3 h; range: 0.5–936) compared to those who survived (median:
3.1 h; range: 0.5–1128). Mortality was 4% among 90 patients with SE
lasting less than one hour, and 24% among 29 patients with SE lasting
more than 24 h (p = 0.033). Positive correlation was found between
the duration of SE and mortality: the longer duration the higher
mortality, with no critical duration after which mortality was not
increased (p = 0.001, r = +0.117). Average number of GTC seizures and
response to AEDswere not signiﬁcantly different among patientswho
did and patients who did not die (p = 0.075–0.823).Table 2
Patients died due to the underlying or co-morbid (in parenthesis) disease complication
Underlying disease (cause) of SE No.
Acute brain infarction (+renal insufﬁciency 1, ketoacidosis 1) 37
Brain metastases (+myocardial infarction 1) 11
Brain anoxia (+myocardial infarction 1, tuberculous pneumonia 1) 10
Acute encephalitis 7
Purulent meningitis 5
Intracerebral hemorrhage 5
Uremia 3
Hyperosmolar coma 3
Hepatic encephalopathy 3
Hypoglycemia 2
Delirium tremens, liver cirrhosis, polyneuropathy 2
Hypertensive encephalopathy 2
Subarachnoid hemorrhage 2
Total3.4. Etiology of death
Table 1 shows the etiology of death. Death was due to serious
underlying (or co-morbid) disease in 79 cases (65.8%) and to the
combination of serious underlying disease and other etiologies in
27 (22.5%) cases (Table 1). In case of 27 patients with multiple
etiologies of death, ‘‘severe’’ etiology was the most important
factor. However, the patients’ condition signiﬁcantly deteriorated
due to development of apnea or RD after therapy (9), emergence of
bacterial infections (sepsis or pneumonia) due to prolonged coma
(8) or combination of more than two factors (10 patients). The
duration of postictal coma was signiﬁcantly longer with patients
who died due to serious underlying disease compared with
patients who did not die (159.3  239.6 and 12.2  48.8 h,
respectively; p = 0.0001). Table 2 shows the list of serious underlying
diseases that caused death in our patients.
Among the remaining 14 patients (11.7%), deathwas not caused
by underlying disease but by convulsions, therapy and coma (4),
therapy (3), therapy and coma (3), coma (2) and convulsions and
coma (2 patients) (Table 1). In those patients, there was no serious
etiology or co-morbidity that could explain death. Actually, SE was
caused by AED withdrawal in 4, and cryptogenic etiology in 10
patients, while etiology of previous chronic epilepsy was
cryptogenic in 9 and chronic non-progressive symptomatic in 5
patients.
In 11 out of 14 patients, prolonged coma (range: 4–1152;
median: 300 h) during SE and/or postictal period was the main
factor that led to death. Coma was clearly aggravated by
convulsions (3 of them died in uninterrupted SE) or depressive
effect of AEDs with 9 patients (due to thiopental anesthesia in 6,s.
Underlying disease (cause) of SE (continued) No.
Cryptogenic (myocardial infarction 1, advanced age) 2
Hyponatremia provoked by water intoxication, not related
to AED (+central pontine myelinoslisis 1)
2
Felbamate: pancytopenia, hemorrhagic diathesis 1
Hodgkin’s disease 1
Intoxication with mianserin (pancreatitis) 1
CNS leucosis 1
Intoxication with disulﬁram and alcohol 1
Epidural hemorrhage 1
Huntington’s chorea 1
Acute intermittent porphyria 1
Alcoholism (liver cirrhosis, variceal hemorrhage) 1
Eclampsia, DIC, intracerebral hemorrhage 1
106
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according to patients’ previous health status occurred during coma
with lethal outcome. They included bacterial pneumonia or sepsis
among 9 of them, pneumothorax and pneumonia in case of 1, and
pulmonary embolism in case of 1 patient.
3.5. Respiratory complications
Respiratory complications occurred in 55 (45.8%) patients who
died: in 27 (22.5%) they were unrelated, and in 28 (23.4%) patients
(14 with RD and 14 with apnea) they were temporarily related to
antistatus therapy. In 47 (85.5%) patients RD or apnea occurred
before and in 8 (14.5%) after the admission to ICU (in later group
during the application of thiopental). Patients were resuscitated
immediately and ventilated until breathing was restored. Only 39
(32.5%) needed prolonged artiﬁcial ventilation due to chronic RD
caused by underlying disease, complications of coma or thiopental
anesthesia. Although almost all patients were intubated in ER,
none of patient was ventilated only because he/she was in SE, or
before emergence of RD. In none of the patients death occurred
directly due to RD or apnea but afterwards due to postanoxic
complications.
Respiratory complications caused by therapy were provoked by
most frequently used AEDs: diazepam, midazolam, and thiopental
(eight patients each treatedwith AED), followed by chlormethiazole
and phenobarbital (two patients each treated with AED), respec-
tively. Overall, AEDs causedmore than one respiratory complication
with themost serious being apnea and cardiac arrest. No association
of any particular AED and death outcome was found.
The most pronounced cases occurred in 3 out of 14 patients
with no serious underlying disease who were admitted with no
cardiac and respiratory function after intravenous injection of
10 mg of diazepam (1) or 15 mg of midazolam (2 patients). Before
the admission, SE lasted 4, 1, and 2 h, respectively. All 3 patients
were resuscitated immediately after admission in ER, ventilated
and monitored in ICU, but died after 24–264 h in postanoxic coma.
3.6. Uninterrupted SE
With 12 patients (1.3%) SE did not stop until it caused death.
Eight patients had initial and 4 intercurrent SE; 9 hadGTC and 3 PM
SE. Table 3 shows etiologies of uninterrupted SE. Although 2–6
(median: 4) ineffective AEDs were applied, SE continued for 13–
936 h (median 184) before death. Two patients died due solely to
serious underlying disease andwith the remaining 10 patients due
to combination of several etiologies.
In summary, convulsions contributed to death with 12 (10%),
complications of therapy with 28 (23.3%) and complications
caused by coma contributed to death with 27 (22.5%) patients
(Table 1).
4. Discussion
Mortality among 13% of patients after the episode of SE is on
lower end of the range, which goes from 9% to 22%.4,8,9,5,10,11Table 3
Causes of uninterrupted SE.
Cause of SE No. Cause of SE (continued) No.
Cryptogenic 3 Purulent meningitis 1
Acute encephalitis 2 Hyperosmolar coma 1
Acute brain infarction 2 Brain Hodgkin’s lymphoma 1
Hepatic encephalopathy 1 Brain metastasis 1
Total 12Probable reasons are lower incidence of initial SE (35% of our
patients) and improved treatment and nursing. In an article from
Switzerland mortality among patients with SE was even lower
(7.6%), despite the larger percent (57%) of patients with initial SE.12
The point is that in better health care systems mortality of SE may
be at the lowest end of the range due to straightforward treatment
of underlying disease and prevention of complications.11,12 In
societies with suboptimal health care system and limited
resources, the best prehospital and hospital organization and well
trained physicians are not always available. This could be the cause
for delayed or inadequate treatment of SE, underlying disease or
complications andworse prognosis for patients with SE and should
also be areas that require more attention.
In meta-analysis of 12 studies, 308 (18%) out of 1686 patients
died.2 In 89%, deathwas due to severe underlying disease, in 2% due
to convulsions, and in remaining 9% due to ‘‘other’’ causes. In later
group of patients (approximately 1 out of 10) there is no comment
regarding the cause of death. The author criticized inevitable
imprecision in attributing outcome to a particular group, making
this distribution only an approximation.2 In order to avoid this
ambiguitywetried toanalyzeevery fatality according to sequenceof
events and identiﬁed underlying disease, vigorous convulsions,
antiepileptic therapy, and coma as independent detrimental factors.
Underlying disease is the primary determinant of SE outcome as
was recognized earlier.9,10,13 In our study, severe underlying
disease was the main etiology of death in 88% of patients.
It appears that SE worsens natural progression of some
underlying diseases. Mortality among patients with acute brain
infarction and SE is three times higher than in patients with acute
brain infarction and no SE.14 This is important because acute brain
infarction is themost common cause of SE among adults, especially
among those older than 60 years.15 Prognosis of other underlying
diseases, such as purulent meningitis, or brain trauma, in the
presence of SE is unfavorable too.16
There is a study showing increased mortality among patients
with PM compared with GTC SE, which was also demonstrated
among our patients. Authors attribute increased mortality to
higher frequency of destructive brain diseases (such as acute brain
infarction) among patients with PM SE.5 Mortality is increased
even in patients with non-convulsive SE, where majority of
patients had severe underlying disease.17,18 These ﬁndings
emphasize dominant inﬂuence of severe underlying disease on
outcome. The effects of convulsions and deranged homeostatic
functions, less pronounced in PM or non-convulsive SE are less
important.19
There is an unresolved dilemma whether the risk of death in
prolonged SE is increased compared to SE of shorter duration.20,21
In a group of 115 patients with favorable outcome, average
duration of SE was 2.4 h, while in a group of 34 patients with
unfavorable outcome (deaths and sequels) the duration was
11.2 h.9 SE was signiﬁcantly longer among patients with severe
symptomatic underlying disease. This makes the conﬁrmation of
independent inﬂuence of prolonged duration of SE on mortality
difﬁcult.22 Our results are in accord with ﬁndings of Knake et al.15
suggesting a positive correlation between the duration of SE and
mortality, with no critical duration after which mortality is
increased. Some authors found no relation between duration and
mortality and associated all deaths with the effects of underlying
disease.10,7 Our point is that in prolonged SE complications occur
more easily due to immobility, unconsciousness or altered
cooperation. In addition, in prolonged SE, it is more probable that
physician will decide to apply more AEDs in higher dose that may
easily provoke serious respiratory complications.
In our group, mortality unrelated to the effect of the underlying
disease occurred in 14 patients. We ascribe those deaths to
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therapy and prolonged coma. Reports of death in SE directly caused
by AEDs are rare.23,24 On the other hand, it is not known whether
intensive and immediate treatment of patient with severe
symptomatic cause of SE increases survival compared to less
intensive treatment. Early therapy with benzodiazepines is
extremely beneﬁcial in discontinuing progression of serial seizures
to SE.25 At least in patients with GTC SE caused by severe
underlying disease, severance of seizures induced by AEDs makes
the treatment of underlying disease easier.2 More importantly, SE
therapy (especially of non-convulsive type) with elderly patients
with severe underlying disease may increase mortality.17,24 It
appears that SE among elderly patients should be treated more
cautiously than in ‘‘standard’’ cases to avoid toxicity and
complications associated with antistatus drugs.24
It is intriguing that the AEDs complications are rarely reported.2
Physicians are rarely aware of complications of benzodiazepines
that may provoke apnea and RD in 3.7-24% of patients.26,23,27,28,29
It was reported that one patient died exclusively due to the apnea
caused by the application of 10 mg of diazepam.23 Reports that pay
heeds to complications or deaths due to other antistatus drugs are
practically absent.2 In our group, respiratory complications of
therapy are the most probable reason of death in three, and in
combination with other complications in additional 25 patients.
However, severe underlying disease could arrange in advance to
respiratory complication of AEDs, at least in some patients.29
Although we found no obvious errors in recommended dosage or
application rate of antistatus drugs, we think that with slower
application rate, apnea or RD can be avoided in majority of
patients. In a similar manner, better management can prevent the
complications caused by convulsions and coma with enhanced
outcome.
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